Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Kristin S. Price"'
Autor:
Katerina Politi, Darren A.E. Cross, Paul D. Smith, Mark A. Lemmon, Sarah B. Goldberg, Franziska Michor, William W. Lockwood, Robert Homer, Arun M. Unni, Susan M. Kaech, Alexandra Kuhlmann, Tyler F. Stewart, Deborah Ayeni, Mmaserame Gaefele, Kumar Dilip Ashtekar, Hina Khan, Kristin S. Price, Dylan Farnsworth, Amy Nagelberg, Iris K. van Alderwerelt van Rosenburgh, Kamrine E. Poels, Maria Emanuela Cuomo, Alexis A. Guernet, Jacqueline H. Starrett
Cell-free DNA Mutation Dataset
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e087b2fda02e3e7f2fdd7bb134ea395
https://doi.org/10.1158/0008-5472.22423677
https://doi.org/10.1158/0008-5472.22423677
Autor:
Katerina Politi, Darren A.E. Cross, Paul D. Smith, Mark A. Lemmon, Sarah B. Goldberg, Franziska Michor, William W. Lockwood, Robert Homer, Arun M. Unni, Susan M. Kaech, Alexandra Kuhlmann, Tyler F. Stewart, Deborah Ayeni, Mmaserame Gaefele, Kumar Dilip Ashtekar, Hina Khan, Kristin S. Price, Dylan Farnsworth, Amy Nagelberg, Iris K. van Alderwerelt van Rosenburgh, Kamrine E. Poels, Maria Emanuela Cuomo, Alexis A. Guernet, Jacqueline H. Starrett
Supplementary Methods, Supplementary Tables S1-5, and Supplementary Figures S1-9
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02dd4a06b12d851a1a5507ab39dac7f9
https://doi.org/10.1158/0008-5472.22423680
https://doi.org/10.1158/0008-5472.22423680
Autor:
Katerina Politi, Darren A.E. Cross, Paul D. Smith, Mark A. Lemmon, Sarah B. Goldberg, Franziska Michor, William W. Lockwood, Robert Homer, Arun M. Unni, Susan M. Kaech, Alexandra Kuhlmann, Tyler F. Stewart, Deborah Ayeni, Mmaserame Gaefele, Kumar Dilip Ashtekar, Hina Khan, Kristin S. Price, Dylan Farnsworth, Amy Nagelberg, Iris K. van Alderwerelt van Rosenburgh, Kamrine E. Poels, Maria Emanuela Cuomo, Alexis A. Guernet, Jacqueline H. Starrett
Osimertinib, a mutant-specific third-generation EGFR tyrosine kinase inhibitor, is emerging as the preferred first-line therapy for EGFR-mutant lung cancer, yet resistance inevitably develops in patients. We modeled acquired resistance to osimertinib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::020e6dd47591fa2fba8059b795f05a5d
https://doi.org/10.1158/0008-5472.c.6511554
https://doi.org/10.1158/0008-5472.c.6511554
Autor:
Mark M. Awad, Pasi A. Jänne, Geoffrey R. Oxnard, Lynette M. Sholl, Mizuki Nishino, Stephen R. Fairclough, Kristin S. Price, Andrew D. Cherniack, Adem Albayrak, Cloud P. Paweletz, Renato Umeton, Deepti Venkatraman, Marina S.D. Milan, Tom Nguyen, Giuseppe Lamberti, Yvonne Y. Li, Ying-Chun Lo, Giulia C. Leonardi, Biagio Ricciuti, Jianwei Che, Liam F. Spurr, Magda Bahcall, Gonzalo Recondo
Supplementary Figure Legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1328adafccdfbb4d67dca43a18bdab9e
https://doi.org/10.1158/1078-0432.22478466.v1
https://doi.org/10.1158/1078-0432.22478466.v1
Autor:
Mark M. Awad, Pasi A. Jänne, Geoffrey R. Oxnard, Lynette M. Sholl, Mizuki Nishino, Stephen R. Fairclough, Kristin S. Price, Andrew D. Cherniack, Adem Albayrak, Cloud P. Paweletz, Renato Umeton, Deepti Venkatraman, Marina S.D. Milan, Tom Nguyen, Giuseppe Lamberti, Yvonne Y. Li, Ying-Chun Lo, Giulia C. Leonardi, Biagio Ricciuti, Jianwei Che, Liam F. Spurr, Magda Bahcall, Gonzalo Recondo
Purpose:Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors (TKI) are poorly understood. We aimed to characterize the genomic mechanisms of resistance to type I and type II MET TKIs and their impact on sequential MET TKI the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d9f6f735866b3000aecf2169c24f8cc
https://doi.org/10.1158/1078-0432.c.6529956
https://doi.org/10.1158/1078-0432.c.6529956
Autor:
Yoshihisa Kobayashi, Chhayheng Chhoeu, Jiaqi Li, Kristin S. Price, Lesli A. Kiedrowski, Jamie L. Hutchins, Aaron I. Hardin, Zihan Wei, Fangxin Hong, Magda Bahcall, Prafulla C. Gokhale, Pasi A. Jänne
Publikováno v:
Nature. 603:335-342
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bfde2ae8f9187c19b713a9b29acbc6c2
https://doi.org/10.1038/s41586-022-04451-4
https://doi.org/10.1038/s41586-022-04451-4
Autor:
Lynette M. Sholl, Geoffrey R. Oxnard, Giuseppe Lamberti, Ying-Chun Lo, Stephen R. Fairclough, Liam F. Spurr, Adem Albayrak, Deepti Venkatraman, Tom C. Nguyen, Renato Umeton, Yvonne Y. Li, Magda Bahcall, Pasi A. Jänne, Marina S.D. Milan, Mark M. Awad, Andrew D. Cherniack, Cloud P. Paweletz, Biagio Ricciuti, Gonzalo Recondo, Jianwei Che, Giulia Costanza Leonardi, Kristin S Price, Mizuki Nishino
Publikováno v:
Clinical Cancer Research. 26:2615-2625
Purpose:Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors (TKI) are poorly understood. We aimed to characterize the genomic mechanisms of resistance to type I and type II MET TKIs and their impact on sequential MET TKI the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f77a1442ed95a93dfcaa6ab0190cd23
https://doi.org/10.1158/1078-0432.ccr-19-3608
https://doi.org/10.1158/1078-0432.ccr-19-3608
Autor:
Yoshihisa, Kobayashi, Chhayheng, Chhoeu, Jiaqi, Li, Kristin S, Price, Lesli A, Kiedrowski, Jamie L, Hutchins, Aaron I, Hardin, Zihan, Wei, Fangxin, Hong, Magda, Bahcall, Prafulla C, Gokhale, Pasi A, Jänne
Publikováno v:
Nature. 603(7900)
RAS family members are the most frequently mutated oncogenes in human cancers. Although KRAS(G12C)-specific inhibitors show clinical activity in patients with cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::89250591810c1ba1a8c05599e2245162
https://pubmed.ncbi.nlm.nih.gov/35302114
https://pubmed.ncbi.nlm.nih.gov/35302114
Autor:
Martin E, Gutierrez, Kristin S, Price, Richard B, Lanman, Rebecca J, Nagy, Irfan, Shah, Shivam, Mathura, Michael, Mulcahy, Andrew D, Norden, Stuart L, Goldberg
Publikováno v:
JCO Precision Oncology
PURPOSE Genomic testing is recognized in national guidelines as essential to guide appropriate therapy selection in metastatic colorectal cancer. Previous studies report adherence to testing guidelines is suboptimal, but current testing rates have no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::66de9045783b94b6230c1a766d7fa25d
https://pubmed.ncbi.nlm.nih.gov/32923867
https://pubmed.ncbi.nlm.nih.gov/32923867